PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Pfizer to build R&D facility in Wuhan, China

Pfizer is expanding its R&D efforts in China and announced plans to build a new facility.

An agreement has been signed to establish a new Pfizer R&D centre in Wuhan, which the firm says represents an expansion of its existing facility in Shanghai. Once the new plant is built, the company expects the number of employees to grow to 200 within three years but gave no details about the financial investment involved.

Pfizer noted that its Wuhan operation will liaise with local research institutes and universities “utilising the rich resources of local talent and existing industry capabilities to develop research collaborations”. It stressed that Shanghai will remain “the operations hub of Pfizer’s R&D effort in China”.

Allan Gabor, the company’s North Asia president, noted that it is the first to establish a significant R&D presence in China’s Central/Western region. He added that the Wuhan centre will be an integral part of Pfizer’s global R&D operations “while being closely aligned with the Chinese government’s strategy on biopharmaceutical industry development in the region.”

The site will be based at the Wuhan National Bioindustry Base, or Biolake, the construction for which started in November last year.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026